Vagus nerve stimulation (VNS) is gaining increasing popularity and credibility as a treatment option for patients with intractable epilepsy. VNS is a relatively recent innovation, however, and like many other incipient developments, it has engendered a number of unresolved controversies and perplexities. Limitations in our current understanding of how VNS works lie at the crux of these uncertainties. In this article, we present our clinical experience with VNS and review the fundamental issues which remain unsettled, such as the mechanism of VNS action, the factors underlying variability in patient outcome, and the selection of ideal candidates for VNS therapy. Although many enigmas persist, VNS has proven to be a safe, feasible, and potentially effective method of reducing seizures in select patient populations. It offers several advantages over extant treatments and, as a result, holds much promise for future therapy of medically refractory epilepsy.
Introduction
Vagus nerve stimulation (VNS) with the Neu rocybernetic Prosthesis (NCP) system (Cyberonics, Webster, Tex., U.S.A.) is emerging as a novel ad junct in the management of patients with intractable seizures. This device delivers intermittent electrical stimulation to the cervical vagus nerve trunk, which secondarily transmits rostral impulses to exert widespread effects on neuronal excitability throughout the central nervous system (Fig. 1) . We have comprehensively reviewed the theoretical background and practical application of VNS in a previous publication.1) In this article, we present the outcome of our clinical experience with the method and examine some of the intriguing questions raised by our results. 
Clinical Experience
To date, we have treated over 50 patients with the NCP device. Seventeen of them participated in the E05 study, a multicenter, double-blinded, ran domized, active control trial of high versus low stimulation parameters conducted between 1995 and 1996.1,7) Eligible subjects in this study had med ically refractory epilepsy with at least six partial onset seizures involving alteration of consciousness (complex partial and/or secondarily generalized convulsions) per month and no more than 21 days between ictal events. Patients were excluded for progressive systemic or neurological disease, cardiac arrhythmia, active pulmonary or peptic ul cer disease, insulin-dependent diabetes, pregnancy, or history of prior left cervical vagotomy.
The mean patient age was 38.5 years (range 21 to 65 years), and the mean duration of epilepsy 31.8 years. The mean baseline seizure frequency was ap proximately one per day, despite an average of 2.6 concomitant antiepileptic medications. Thus, all patients had longstanding, medically refractory sei zures resulting in severe incapacitation. After a 3 month baseline to document seizure fre quency, each patient underwent placement of an NCP pulse generator in the chest connected to heli cal leads applied to the left cervical vagus nerve trunk (Fig. 1) . The surgical protocol has been de scribed elsewhere.1) Typically, the procedure is con ducted under general anesthesia and lasts less than 2 hours. While it can be performed as an outpatient procedure,'22) it may be desirable to observe patients overnight for vocal cord dysfunction, dysphagia, respiratory compromise, or seizures induced by the anesthetic, although these complications are infre quent.31
All surgeries in our study were successful, un eventful, and without adverse sequelae. Postopera tively, patients were observed for 2 weeks to allow for wound healing, resolution of local edema, and proper electrode fixation to the nerve. Patients were subsequently randomized to receive either high or low parameters of stimulation ( The two groups were compared during a 3-month double-blinded treatment phase. During this time, patients were maintained on stable regimens of the antiepileptic medications they had been taking preoperatively. At the conclusion of this period, subjects who were initially randomized to low stimulation settings were converted to the higher stimulation protocol during a 15-month partial crossover extension trial. Thus, during the latter phase, all participants received high stimulation settings. Medication changes were made in 12 patients in the course of this phase. Seven patients were randomized to receive the high stimulation protocol. After 3 months of follow up, the change in seizure frequency for this group ranged from -100% to +22%, with a mean of -71% (Fig. 2) . At the end of the extension trial (after 18 months of stimulation), the range was 100% to -18% and the mean -81% (Fig . 3) . Five (71%) of these patients experienced a greater than 75% reduction in seizure frequency at 18 months, and one (14%) has remained seizure free after more than 3 years of follow-up. These results compare favora bly with the multicenter E05 study as a whole, which observed a 28% mean reduction in seizure fre quency among patients in the high group after 3 months, with some centers actually reporting an in crease in seizure frequency compared with base line.7)
For the 10 patients randomized to low stimulation, the change in seizure frequency after 3 months of follow-up ranged from -75% to +108%, with a mean of -6% (Fig. 2) . The difference in mean sei zure reduction between the two treatment groups was statistically significant (p = 0.004). When these patients were subsequently converted to higher stimulation settings, the range was -98% to +35%, with a mean of -34% (Fig. 3) The exact mechanism by which VNS modulates seizure activity and its locus of action have been reviewed elsewhere but remain uncertain.1,20,21) Although the vagus nerve is generally regarded as an efferent projection that innervates the larynx and provides parasympathetic control of the heart, lungs, and gastrointestinal tract, the majority of its fibers are sensory. While it was initially proposed that VNS works by recruiting afferent C-fibers and A-delta fibers within the nerve,27) this contention has been recently challenged by observations that VNS retains its antiepileptic effects despite selective de struction of these small unmyelinated fibers by treatment with capsaicin.131
Vagal afferent fibers originate from receptors in the viscera and terminate in diffuse areas of the central nervous system, many of which are potential sites of epileptogenesis. These include the cerebel lum, diencephalon, amygdala, hippocampus, insular cortex, and multiple brainstem centers. Some of these projections relay through the nucleus tractus solitarius, while others form direct, monosynaptic connections with their targets.1,20,21) Although it remains unclear which of these pathways underlie the mechanism of VNS action, the locus ceruleus and raphe nucleus appear to be key intermediaries, since bilateral chemical lesions of these centers abolish the seizure-suppressing effects of VNS ther apy in animal models. 13) These results imply that norepinephrine and serotonin, which are diffusely released by the locus ceruleus and raphe nucleus, respectively, may mediate the anticonvulsant actions of VNS. Indeed, these two neurotransmitters are known to modulate seizure threshold in some parts of the brain by in ducing interneurons to release gamma-amino butyr ic acid (GABA), leading to widespread inhibition of neuronal excitability throughout the brain.18) However, the levels of GABA and serotonin metabolites in the cerebrospinal fluid of patients undergoing VNS appears to be inversely correlated with the efficacy of treatment, and the neurotrans mitter systems that mediate the antiepileptic ac tions of VNS remain uncertain.1,2)
Recently, some animal studies have suggested that the mechanism of VNS action derives from cardiac rate and conduction changes leading to transient cerebral ischemia, rather than direct effects on neu rotransmitter release or neuronal membrane con ductance. 23 A recent meta-analysis of 454 patients enrolled in one of five controlled clinical trials suggests that the response of individual patients to VNS varies great ly.16) While a few subjects enjoy complete seizure cessation, others derive no benefit, and the remain der experience intermediate results.1) Because such variability is inherent to trials of many anticonvul sant therapies, a standard measure of efficacy has been the 50% responder rate (the proportion of sub jects who experience a 50% reduction of baseline seizure frequency). In the meta-analysis of VNS, the 50% response rate was approximately 40% after 3 years of follow-up.16) While this figure is similar to the initial results of many new drug trials,13) it remains unclear why some patients respond to VNS and others do not. Early experiments in animals revealed that inter mittent stimulation of the vagus nerve could sup press the onset of new seizures, in addition to shortening seizure duration and halting seizure progression. VNS is thus both a preventative (an tiepileptic) and an abortive (anticonvulsant) form of therapy, with the period of seizure suppression out lasting the stimulus duration.18) The sustained an tiepileptic effects have been confirmed by PET scans, serial electroencephalograms, and markers of neuronal gene transcription.1, 12) These observations form the basis of the stimula tion parameters currently utilized in clinical prac tice. In the E05 trial, for instance, the settings in the high group were derived from pilot data and animal studies which suggested a high likelihood of effica cy, while those in the low group were intended to be perceptible as a tingling sensation in the neck (to maintain patient blinding), but less effective (Table  1) . Thus, this study employed an active control, rather than a true placebo.
The rationale underlying these stimulation pro tocols has recently been challenged.28) In addition to its anticonvulsive effects, VNS also inhibits the nociceptive reflex (NR) in anesthetized rats, elicited by delivering a strong stimulus to the tail or hind paw. By titrating the parameters of VNS to the endpoint of NR inhibition, new stimulation settings have been proposed, based on the premise that maximal activation of afferent C fibers mediates both the anticonvulsive and antinociceptive effects of VNS.28) Currently, the selection of stimulation parameters in particular subjects remains empiric. Typically, patients receive 30 second trains of 30 Hz, 500 microsecond pulses separated by 5 minute intervals between stimulation, with current adjustments ac cording to individual tolerance and efficacy. However, it is possible that the full potential of VNS has not yet been realized, secondary to our relative ignorance about the ideal dosing parameters. Thus, further experimentation with alternative stimulation paradigms is needed to optimize the therapeutic outcome of VNS. 19) The timing of stimulus adjustment may also be an important factor in determining outcome. As men tioned, the disparity between our two treatment groups at the end of the extension trial could be ex plained by differences in baseline seizure fre quency between the two cohorts. Alternatively, In the United States, VNS is only approved as an adjunctive treatment for intractable seizures of par tial onset in patients over the age of 12. However, multiple studies confirm the safety, tolerance, and efficacy in children as young as 3 years old.10,11) Patients with Lennox-Gastaut9,17) and other types of primary generalized epilepsies have also derived significant benefit from VNS, although preliminary experience with infantile spasms has been disap pointing.5) Of note, VNS has been used successfully in patients who have failed to respond to other sur gical procedures such as lobectomies, topectomies, corpus callosotomies, multiple subpial transections, and functional hemispherectomy,6) confirming the potential efficacy of VNS in highly refractory patient populations. 
